Press Releases



    • JAN 14 2019

    Oncoceutics Expands Patent Family to Include Use of ONC201 in H3 K27M-Mutant Gliomas

    Philadelphia, PA (January 14, 2019) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #10,172,862 for the use of ONC201 to treat midline gliomas having a histone 3 K27M (H3 K27M) mutation. This patent extends the ONC201 patent life through at least 2038. This patent is the eighth

    • JAN 11 2019

    Publication Reports Role of Dopamine Receptors in Cancer and ONC201 Response

    Philadelphia, PA (January 11, 2019) – Oncoceutics, Inc. announced the publication of a research article in the scientific journal Clinical Cancer Research that describes the dysregulation of specific dopamine receptors by human cancers. The article also defines therapeutic opportunities associated with selective targeting of these receptors in tumors by ONC201 and other imipridones, Oncoceutics’ novel